Literature DB >> 19258230

[Cognitive impairments and breast cancer: a critical review of the literature].

S Vandenbossche1, P Fery, D Razavi.   

Abstract

Since the 1980's, women treated for breast cancer are reporting moderate cognitive impairments during and after chemotherapy. These cognitive impairments may be related to chemotherapy but also to hormone therapy, psychological distress, fatigue... This work is a critical review of the literature, which reports types of impairments, frequency, severity, causes and mechanisms involved in this issue. It also provides an update on potential moderators factors, which may be associated with mild cognitive impairments and various tools for their assessment used in the studies. These studies--selected between 1997 and 2008--show that cognitive impairments are frequently reported by patients with breast cancer but that the mechanisms are still poorly understood and that the methods of assessment are very heterogeneous and difficult to compare. This review indicates that future studies should include more homogenous patient groups, be longitudinal, use more sensitive and specific assessment tools and control moderators factors that play a role in impairment in cognitive function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258230     DOI: 10.1684/bdc.2008.0818

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  Potential Molecular Biomarkers of Central Nervous System Damage in Breast Cancer Survivors.

Authors:  Maria Pospelova; Varvara Krasnikova; Olga Fionik; Tatyana Alekseeva; Konstantin Samochernykh; Nataliya Ivanova; Nikita Trofimov; Tatyana Vavilova; Elena Vasilieva; Maria Topuzova; Alexandra Chaykovskaya; Albina Makhanova; Anna Mikhalicheva; Tatyana Bukkieva; Kenneth Restor; Stephanie Combs; Maxim Shevtsov
Journal:  J Clin Med       Date:  2022-02-24       Impact factor: 4.241

2.  Preventive effect of oral magnesium in postmastectomy pain: protocol for a randomised, double-blind, controlled clinical trial.

Authors:  Véronique Morel; Dominique Joly; Christine Villatte; Bruno Pereira; Gisèle Pickering
Journal:  BMJ Open       Date:  2018-10-04       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.